Navigation Links
The Largest Private Funder Of Melanoma Research Receives Vital Support From Activist Jeffrey Epstein
Date:5/29/2012

NEW YORK, May 29, 2012 /PRNewswire/ -- The Melanoma Research Alliance (MRA) has just received a pivotal donation from The Jeffrey Epstein VI Foundation to further its support of melanoma research around the world.

The MRA is the largest private funder of melanoma research worldwide. The Alliance funds programs that show significant advances in the prevention, diagnosis, staging and treatment of melanoma, including progress in the causes of carcinogenesis, skin screening, biomarkers, imaging, immunotherapy, molecularly targeted therapy and combination therapy. Since 2008, the MRA has granted approximately $38 million to over 134 programs and 65 institutions.

What is unique about the MRA though is that it aims to support not just the most effective research it can find but the most efficient. Furthermore, all funding goes directly to sponsoring research, as opposed to a large administrative staff.

"Efficiency in medical research is critical," Jeffrey Epstein remarked, whose own foundation focuses on supporting cutting edge science. "Scientists have to have financial autonomy to prioritize their goals. Too many of our best institutes are handicapped by bureaucratic directives which don't always foster the best results."

Today, melanoma is the deadliest of all skin cancers. It also has the highest rate of occurrence as compared to other cancers in the US. The rate of long term survival however, has remained static over the last forty years at an appallingly low rate of 15%.

Some of the promising programs that received funding from the MRA via the Jeffrey Epstein VI Foundation include, Rockefeller University for therapeutic targeting of novel metastatic microRNAs in human melanoma, Georgetown University for kinetics and effects of vemurafenib on intratumoral immunity, the Ludwig Institute for Cancer Research, Melbourne-Austin Branch for targeting inducible invasive cells in melanoma and Yale University, School of Medicine for regulatory macrophages: a new therapeutic target in melanoma.

"These new grants address critical issues in the prevention, detection, staging and treatment of melanoma that are central to making further clinical advances against this disease," said MRA Chief Science Officer Dr. Suzanne L. Topalian. "This is a time of unprecedented opportunity in melanoma research, and these projects are anticipated to result in near term benefits for patients."

http://www.jeffreyepstein.org


'/>"/>
SOURCE www.jeffreyepstein.org
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
2. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
3. Henry Schein Ranks #303 In 2012 FORTUNE 500® Ranking Of Americas Largest Corporations
4. Linet Awarded New Technology Agreement from Novation, the Nations Largest Healthcare Purchasing Organization
5. Largest Neurosurgical Center in Russia Acquires Elektas Leksell Gamma Knife Perfexion
6. Medical Alarm to Begin Fulfillment of MediPendant™ Against Largest Purchase Order - Announces Additional Warrant Cancellations
7. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
8. Outreach Services Merger With Cardon Healthcare Creates Largest Provider of Eligibility Services to Hospitals
9. Vets First Choice Acquires VetCentric to Form Nations Largest Online Veterinary Partner Pharmacy and Marketing Services Provider
10. Unity Management Group, Inc. Receives Contract From Sun Pharmaceutical Indias Largest Pharmaceutical Companies for $105,000
11. RNL Opens the Worlds Largest Stem Cell Medical Center in Beijing, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):